The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors.

[1]  Michel Bouvier,et al.  Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. , 2005, Trends in pharmacological sciences.

[2]  M. Kampa,et al.  Opioid-somatostatin interactions in regulating cancer cell growth. , 2005, Frontiers in bioscience : a journal and virtual library.

[3]  S. EL-KADY,et al.  Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma. , 2005, British journal of anaesthesia.

[4]  Hai-Lin Liu,et al.  Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. , 2004, Acta pharmacologica Sinica.

[5]  M. Kampa,et al.  Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. , 2004, Journal of hepatology.

[6]  M. Bouvier,et al.  Roles of G‐protein‐coupled receptor dimerization , 2004, EMBO reports.

[7]  P. Lakatos,et al.  Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[8]  P. Lakatos,et al.  Rising plasma nociceptin level during development of HCC: a case report. , 2004, World journal of gastroenterology.

[9]  M. Grant,et al.  The toxicity of opiates and their metabolites in HepG2 cells. , 2003, Chemico-biological interactions.

[10]  U. Stürzebecher,et al.  Tyr‐c[D‐Orn‐Tyr(Bzl)‐Pro‐Gly]: a novel antiproliferative acting somatostatin receptor agonist with μ‐opioid receptor‐sensitizing properties , 2003, British journal of pharmacology.

[11]  S. Fan,et al.  A randomized placebo‐controlled study of long‐acting octreotide for the treatment of advanced hepatocellular carcinoma , 2002, Hepatology.

[12]  D. Panagiotakos,et al.  The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. , 2002, Hepato-gastroenterology.

[13]  Manuela Pfeiffer,et al.  Heterodimerization of Somatostatin and Opioid Receptors Cross-modulates Phosphorylation, Internalization, and Desensitization* , 2002, The Journal of Biological Chemistry.

[14]  M. Kampa,et al.  Receptorphin: A conserved peptide derived from the sequence of the opioid receptor, with opioid displacement activity and potent antiproliferative actions in tumor cells , 2001, BMC pharmacology.

[15]  L. Tang,et al.  [Inhibition effects of octreotide on the growth of hepatocellular carcinoma in vitro and in vivo]. , 2001, Zhonghua yi xue za zhi.

[16]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[17]  L. Devi,et al.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  W. Scheithauer,et al.  Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. , 2000, International journal of oncology.

[19]  E. Kouroumalis,et al.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study , 1998, Gut.

[20]  H. Kaneko,et al.  Effect of intragastric administration of beta-endorphin on thyrotropin-releasing hormone and somatostatin release into gastric lumen of rats , 1998, Journal of Gastroenterology.

[21]  E. Castanas,et al.  Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. , 1997, European journal of pharmacology.

[22]  M. Adler,et al.  Interaction of cholecystokinin and somatostatin with a selective μ-opioid agonist and μ- and κ- antagonists in thermoregulation , 1997, Brain Research.

[23]  C. Stournaras,et al.  Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth , 1996, Journal of cellular biochemistry.

[24]  E. Castanas,et al.  Antiproliferative and receptor binding properties of α- and β-casomorphins in the T47D human breast cancer cell line , 1996 .

[25]  E. Castanas,et al.  Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. , 1995, Cancer research.

[26]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[27]  D. Carballo,et al.  Response of the human hepatic tissue cultures Hep-G2 and WRL-68 to cocaine. , 1995, Journal of pharmacological and toxicological methods.

[28]  G. Liapakis,et al.  Characterization of [125I]Tyr11-Somatostatin binding sites in the rabbit retina , 1992, Neuropeptides.

[29]  F. Fagnoni,et al.  Naloxone abolishes the inhibiting effect of somatostatin on the release of oxytocin evoked by insulin-induced hypoglycemia in humans. , 1989, Metabolism: clinical and experimental.

[30]  V. Hruby,et al.  Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions. , 1987, The Journal of pharmacology and experimental therapeutics.

[31]  P. Giraud,et al.  Interaction of Opiates with Opioid Binding Sites in the Bovine Adrenal Medulla: I. Interaction with δ and μ Sites , 1985 .

[32]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.